paclitaxel has been researched along with Debility in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cabezas-Camarero, S; Cabrera-Martin, MN; Perez-Segura, P; Saiz-Pardo Sanz, M | 1 |
| Álvarez, R; Carrato, A; Díaz, R; García, A; Hidalgo, M; Laquente, B; Macarulla, T; Muñoz, A; Sastre, J | 1 |
| Crane, S; Gajra, A; Klepin, HD; Miller, AA; Petty, WJ; Ruiz, J; Tooze, JA | 1 |
| Campbell, GB; Courtney-Brooks, M; Donovan, HS; Hay, CM; Taylor, SE; Wang, L | 1 |
1 review(s) available for paclitaxel and Debility
| Article | Year |
|---|---|
Management and supportive treatment of frail patients with metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Frail Elderly; Frailty; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2019 |
3 other study(ies) available for paclitaxel and Debility
| Article | Year |
|---|---|
Major and durable response to second-line pembrolizumab-carboplatin-paclitaxel in an oral cavity cancer patient.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Frailty; Head and Neck Neoplasms; Humans; Malnutrition; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck | 2021 |
Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Frailty; Geriatric Assessment; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proportional Hazards Models | 2019 |
Chemotherapy in older adult gynecologic oncology patients: Can a phenotypic frailty score predict tolerance?
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cohort Studies; Endometrial Neoplasms; Female; Frailty; Humans; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Prospective Studies | 2019 |